Navigation Links
Arpida Presents Preclinical Data on AR-2474 at ICAAC
Date:9/21/2007

REINACH and BASEL, Switzerland, September 21 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) presented several preclinical studies on its novel topical antibiotic AR-2474 at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. ICAAC is a major scientific conference where thousands of scientists and clinicians from all over the world gather to discuss the latest developments in the field of infectious diseases.

AR-2474 is a novel synthetic antibacterial currently under development for topical indications including treatment of infections and prevention of transmission of the "superbug" MRSA. AR-2474 is a diphenyl urea with unique properties.

F1-2100: The topical activity and potency of AR-2474 was compared with the gold standard mupirocin (Bactroban(R)) in two preclinical models of MRSA infection of the skin and of nasal decolonisation. In both models, a preliminary topical formulation of AR-2474 was demonstrated to be as efficacious as mupirocin.

F1-2094, F1-2095, F1-2096, F1-2097, F1-2100A: The in vitro microbiological activity of AR-2474 and of other compounds of the class was assessed in-house and by leading laboratories against large panels of clinical isolates. AR-2474 showed potent activity against methicillin susceptible and resistant staphylococci including nosocomial and community S. aureus isolates. Importantly, AR-2474 exhibits no cross-resistance with other classes of currently used topical treatments. The compound also exhibited potent activity against Group A and B streptococci, enterococci, pneumococci and other important pathogens responsible for causing infections of the skin, eye and mouth.

F1-2099: AR-2474 demonstrated little or no propensity for resistance development. No resistant mutants to AR-2474 could be selected using different methodologies.

F1-2098: The data showed that AR-2474 is bactericidal, exhibits a post antibiotic effect and shows no antagonism wi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... ... most complex toxicology study designs in South Korea , ... Cedar Knolls, NJ and Daejeon, South Korea (PRWEB) ... solutions and the developer of Pristima™ the premier preclinical solution on the market, is ...
... , , ABBOTT PARK, Ill., Aug. ... expansion of the company,s XIENCE V(R) USA post-approval study designed to ... Everolimus Eluting Coronary Stent System in a real-world clinical setting out ... from the XIENCE V USA trial to be eligible to cross ...
... , , , ... MON ) R&D pipeline is on the verge of a technology ... for growers and has the company poised to meet its goals ... and president, will tell investors today. , , ...
Cached Biology Technology:Korea Institute of Toxicology Implementing Xybion's Pristima™ 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 3Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7
(Date:8/20/2014)... leaves, photosystem 1 (PS1) absorbs light and its ... carbon dioxide to biomass. Photovoltaic devices, mostly build ... but produce electricity. One approach for the development ... the semi-conductor with the isolated membrane protein complexes ... a highly stable PS1 from thermophilic cyanobacteria that ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... This news release is available in German . ... power are inherently intermittent energy sources. If a large amount ... in the future, excess energy will have to be stored ... for. However, existing storage capacities are far from adequate for ... better technologies. One important focus lies on battery systems that ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A) today announced that its breakthrough Human Genome CGH ... Peter MacCallum Cancer Centre in a three-year study designed ... lining of the chest, the abdominal cavity and around ... Due to its active mining and manufacturing of asbestos ...
... The human fossil evidence from the Mladec Caves in Moravia, ... proven for the first time, through modern radiocarbon dating, to ... modern humans in Europe. , A team of researchers from ... Vienna in Austria and from the Washington University in St. ...
... Studying phage, a primitive class of virus that infects ... researchers have gained insight into the driving force behind ... in the past to occur through the release of ... all phages (also known as bacteriophages) are formed of ...
Cached Biology News:Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma 2Oldest cranial, dental and postcranial fossils of early modern European humans confirmed 2Basis for DNA ejection from single phage particles 2
Mouse/Rat WNK1 Affinity Purified Polyclonal Ab...
Recalibration of HL-2000-CAL products...
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
LAL Chromogenic Endpoint assay...
Biology Products: